Dyadic International Inc, DE(DYAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 4:00 PM ET (Korea 10/22 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.21 | Insider Own | 23.02% | Shs Outstand | 36.4M | Perf Week | -2.49% |
| Market Cap | 0.02B | Forward P/E | 13.33 | EPS next Y | 121.43% | Insider Trans | -2.83% | Shs Float | 30.8M | Perf Month | - |
| Enterprise Value | 0.02B | PEG | 0.21 | EPS next Q | -0.04 | Inst Own | 20.04% | Short Float | 0.58% | Perf Quarter | -66.94% |
| Income | -0.01B | P/S | 4.22 | EPS this Y | 39.13% | Inst Trans | -3.27% | Short Ratio | 0.95 | Perf Half Y | -51.81% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 64.84% | ROA | -103.88% | Short Interest | 0.18M | Perf YTD | -57.45% |
| Book/sh | -0.07 | P/C | 3.43 | EPS past 3/5Y | 13.04% 7.84% | ROE | -2826.92% | 52W High | -75% ($1.60) | Perf Year | -63.96% |
| Cash/sh | 0.12 | P/FCF | - | Sales past 3/5Y | 1.79% 14.04% | ROIC | -287.21% | 52W Low | 17.61% ($0.34) | Perf 3Y | -75.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -14.12% | Gross Margin | 16.24% | Volatility(W/M) | 13.67% 10.84% | Perf 5Y | -91.17% |
| Dividend TTM | - | EV/Sales | 4.32 | Sales Y/Y TTM | -8.05% | Oper. Margin | -194.5% | ATR (14) | 0.05 | Perf 10Y | -75.61% |
| Dividend Ex-Date | - | Quick Ratio | 1.65 | EPS Q/Q | 2.18% | Profit Margin | -200.46% | RSI (14) | 36.45 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.65 | Sales Q/Q | -0.57% | SMA20 | -7.17% ($0.43) | Beta | 1.08 | Target Price | $5.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | -22.93% ($0.52) | Rel Volume | 0.36 | Prev Close | $0.39 |
| Employees | 5 | LT Debt/Eq | - | EPS/Sales Surpr. | -71.43% -6.28% | SMA200 | -48.71% ($0.78) | Avg Volume(3M) | 0.19M | Price | $0.4 |
| IPO | 2004/11/5 | Option/Short | Yes/Yes | Trades | 230 | Volume | 67,310 | Change | 3.87% |
🧫 Dyadic International () is a biotech company whose core asset is C1, a fungal-based protein production platform. It aims to mass-produce proteins for vaccines and therapeutics quickly and affordably, and has recently been expanding its commercial reach into functional proteins for food, nutrition, and wellness applications while rebranding itself as Dyadic Applied BioSolutions.
Over the past 1 year, on the lower side
75% below its 1-year high.
Traded less than usual. That is 36% of its average volume.
DYAI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $422. Peers typically go for $1,173.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #475 of 595 in the industry
Based on market cap of $16M.
KTTA#474 Pasithea Therapeutics Corp $16M PER - DYAI#475 Dyadic International Inc, DE $16M PER - 
NCEL#476 NewcelX Ltd $16M PER - 
RADX#477 Radiopharm Theranostics Ltd ADR $15M PER - 
AKTX#478 Akari Therapeutics Plc ADR $15M PER - 
FAQ
What kind of company is DYAI?
DYAI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DYAI?
The market cap of DYAI is approximately $16M, ranking 5,291 within its sector.
What is the 52-week high and low for DYAI?
DYAI has recorded a 52-week high of $1.60 and a low of $0.34.
